BI-4142 Chemical Structure oral HER2 exon 20 mutants selective inhibitor - Boehringer Ingelheim RCV, Vienna, AT

oral HER2 exon 20 mutants selective inhibitor

tumor regression in the HER2YVMA xenograft model

from 12k compounds in-house library screening and opt

Nat. Cancer

Boehringer Ingelheim RCV, Vienna, AT

Context. BI-4142 (Boehringer Ingelheim) is a HER2 exon 20 insertion mutant inhibitor being developed for non-small cell lung cancer (NSCLC). Despite the general advances made in HER2-targeted therapy and…


 this content is exclusive to
Premium members

Upgrade to a Premium Drug Hunter membership to unlock the full content and start reading now.